These results suggest that in addition to downregulating the proliferation, invasion, and migration of glioma cell lines in vitro, treatment with the GSTA4 inhibitor curzerene also leads to mitigation of tumor growth, invasion, and viability in vivo. Here, GSTA4 is linked to neoplasm.